Department of Palliative Medicine, RWTH Aachen University, Pauwelsstrasse 30, 52074 Aachen, Germany.
Support Care Cancer. 2012 Feb;20(2):325-33. doi: 10.1007/s00520-011-1084-1. Epub 2011 Jan 28.
Patients with advanced cancer are highly susceptible to infections. The decision whether to treat an active or suspected infection or to withhold or withdraw an antibiotic treatment in end-of-life care may be difficult. In order to quantify the antimicrobial prescribing practices and decision-making processes in palliative care units in Germany, a survey was performed as part of the Hospice and Palliative Evaluation in 2006.
With a specifically designed questionnaire, 448 patients for whom an active or suspected infection and antibiotic treatment was discussed were documented. Data on the use of and indication for antibiotic treatment and the decision-making on withdrawal or withholding of antibiotic therapy were collected.
286 (63.8%) received an antibiotic therapy. In 88 cases, withdrawal of an ongoing treatment was documented. The most frequent reasons for withdrawal were: deterioration of general status (41.4%), inefficiency of therapy (25.7%), and explicit wish of patient (14.3%; multiple answers possible). Outcome of antimicrobial therapy was rated poor or very poor for a fifth of the cases and accordingly, antibiotics were more likely to be withdrawn if the clinical success was considered to be poor. The initiation of therapy was often decided by physicians solely, whereas withdrawing and withholding therapy demanded more often involvement of other team members in the decision-making process.
The initiation of therapy seems to be easier than withdrawing and withholding, as involvement of other team members in the decision-making process was then sought more often. When antibiotics were given until death, the indication should be reconsidered because of a possibly undesirable prolongation of the dying process. Clinical practice may benefit from clear definitions of treatment goals and outcome criteria to better evaluate the necessity for and success of antimicrobial treatment.
晚期癌症患者极易感染。在生命末期护理中,决定是否治疗活动性或疑似感染,或停止或撤回抗生素治疗可能会很困难。为了量化德国姑息治疗病房中的抗菌药物处方实践和决策过程,在 2006 年的临终关怀和姑息治疗评估中进行了一项调查。
通过专门设计的问卷,记录了 448 名正在讨论活动性或疑似感染和抗生素治疗的患者。收集了抗生素治疗的使用和适应证以及停止或撤回抗生素治疗的决策的数据。
286 例(63.8%)接受了抗生素治疗。有 88 例记录了正在进行的治疗的停药。停药最常见的原因是:一般状况恶化(41.4%)、治疗无效(25.7%)和患者明确要求(14.3%;可能有多个答案)。五分之一的病例对抗菌药物治疗的结果评价为差或极差,因此,如果临床疗效被认为较差,则更有可能停止抗生素治疗。治疗的启动通常由医生单独决定,而停止和停止治疗则需要更多的团队成员参与决策过程。
启动治疗似乎比停止和停止治疗更容易,因为更多的团队成员会参与决策过程。当抗生素一直用到死亡时,应重新考虑适应证,因为这可能会延长死亡过程。临床实践可能受益于明确的治疗目标和结果标准的定义,以更好地评估抗菌治疗的必要性和成功率。